Key PointsEli Lilly’s impressive run looks likely to continue over the next few years.

2 Growth Stocks to Buy in November Without Any Hesitation

(RTTNews) - Nxera Pharma Co., Ltd. (4565.T) said Wednesday its U.K. subsidiary signed an exclusive global licensing agreement with AbbVie Inc. (ABBV) for its EP4 agonist program, including NXE0033744.

Nxera Signs AbbVie Deal For IBD Drug Candidate With $100 Mln Upfront, Plus Milestones 

Key PointsAbbVie survived its loss of Humira, and its profits are soaring.

The Best Dividend Stocks to Buy With $5,000 in November

Key PointsAbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products.

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

(RTTNews) - Brise Pharmaceuticals Co., Ltd. (Brise), a clinical-stage biopharmaceutical, provided an update on its exclusive license agreement with AbbVie Inc. (ABBV), which the companies entered into in 2024.

AbbVie, Brise Expand Migraine Drug Partnership 

Key PointsAbbVie’s ABBV-466 nearly doubled Skyrizi’s Crohn’s remission rate in a Phase 2 study.

Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. News